Literature DB >> 12365880

Psychological intervention and antidepressant treatment in smoking cessation.

Sharon M Hall1, Gary L Humfleet, Victor I Reus, Ricardo F Muñoz, Diane T Hartz, Roland Maude-Griffin.   

Abstract

BACKGROUND: Sustained-release bupropion hydrochloride and nortriptyline hydrochloride have been shown to be efficacious in the treatment of cigarette smoking. It is not known whether psychological intervention increases the efficacy of these antidepressants. This study compared both drugs with placebo. It also examined the efficacy of these 2 drugs and placebo with and without psychological intervention.
METHODS: This was a 2 (medical management vs psychological intervention) x 3 (bupropion vs nortriptyline vs placebo) randomized trial. Participants were 220 cigarette smokers. Outcome measures were biologically verified abstinence from cigarettes at weeks 12, 24, 36, and 52.
RESULTS: Psychological intervention produced higher 7-day point-prevalence rates of biochemically verified abstinence than did medical management alone. With the use of point-prevalence abstinence, both nortriptyline and bupropion were more efficacious than placebo. On rates of 1-year continuous abstinence, the 2 drugs did not differ from each other or from placebo. Psychological intervention did not differ from medical management alone on rates of 1-year continuous abstinence.
CONCLUSIONS: Both nortriptyline and bupropion are efficacious in producing abstinence in cigarette smokers. Similarly, psychological intervention produces better abstinence rates than simple medical management. Both drugs, and psychological intervention, have limited efficacy in producing sustained abstinence. The data also suggest that combined psychological intervention and antidepressant drug treatment may not be more effective than antidepressant drug treatment alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12365880     DOI: 10.1001/archpsyc.59.10.930

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  54 in total

Review 1.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

Review 2.  Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review.

Authors:  John R Hughes; Matthew J Carpenter; Shelly Naud
Journal:  Nicotine Tob Res       Date:  2010-05-26       Impact factor: 4.244

Review 3.  Applying the tripartite model of anxiety and depression to cigarette smoking: an integrative review.

Authors:  Katherine J Ameringer; Adam M Leventhal
Journal:  Nicotine Tob Res       Date:  2010-10-29       Impact factor: 4.244

Review 4.  Recent advances in the psychotherapy of addictive disorders.

Authors:  Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

5.  Predictors of 12-month outcome in smokers who received bupropion sustained-release for smoking cessation.

Authors:  Gary E Swan; Lisa M Jack; Harold S Javitz; Tim McAfee; Jennifer B McClure
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis.

Authors:  M E Mooney; V I Reus; J Gorecki; S M Hall; G L Humfleet; R F Muñoz; K Delucchi
Journal:  Clin Pharmacol Ther       Date:  2007-08-08       Impact factor: 6.875

7.  Comparing gain- and loss-framed messages for smoking cessation with sustained-release bupropion: a randomized controlled trial.

Authors:  Benjamin A Toll; Stephanie S O'Malley; Nicole A Katulak; Ran Wu; Joel A Dubin; Amy Latimer; Boris Meandzija; Tony P George; Peter Jatlow; Judith L Cooney; Peter Salovey
Journal:  Psychol Addict Behav       Date:  2007-12

Review 8.  Ethical concerns about non-active conditions in smoking cessation trials and methods to decrease such concerns.

Authors:  John R Hughes
Journal:  Drug Alcohol Depend       Date:  2008-12-06       Impact factor: 4.492

9.  Bupropion and cognitive-behavioral treatment for depression in smoking cessation.

Authors:  Richard A Brown; Raymond Niaura; Elizabeth E Lloyd-Richardson; David R Strong; Christopher W Kahler; Ana M Abrantes; David Abrams; Ivan W Miller
Journal:  Nicotine Tob Res       Date:  2007-07       Impact factor: 4.244

Review 10.  Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence.

Authors:  Terril L Verplaetse; Andrea H Weinberger; Philip H Smith; Kelly P Cosgrove; Yann S Mineur; Marina R Picciotto; Carolyn M Mazure; Sherry A McKee
Journal:  Nicotine Tob Res       Date:  2015-03-11       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.